Study guide

4.6 Post-Treatment Surveillance for Cancer Recurrence

Advanced Oncology Certified Nurse Practitioner AOCNP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide

2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening

2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling

3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging

3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment

4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship

4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence

5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy

5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology

7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy

7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies

8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response

8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety

9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions

10 Chapter 10: Supportive Care - Symptom & Comorbidity Management

10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management

11 Chapter 11: Oncologic Emergencies

11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

12 Chapter 12: Psychosocial Issues

12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources

13 Chapter 13: Professional Practice & Roles of the APRN

13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education

4.6 Post-Treatment Surveillance for Cancer Recurrence

Key Takeaways Explain This Topic AI

Surveillance is justified only when earlier detection changes outcome, which is why intensive imaging is standard after colorectal resection but not after curative breast surgery in an asymptomatic patient.

ASCO and NCCN recommend against routine surveillance imaging and tumor markers in asymptomatic breast cancer survivors; history, physical examination, and annual mammography are the standard.

Carcinoembryonic antigen every 3 to 6 months plus CT of the chest, abdomen, and pelvis is standard surveillance after curative-intent resection of stage II or III colorectal cancer, because resectable oligometastatic recurrence is curable.

A rising tumor marker requires confirmation on a repeat draw and correlative imaging before any treatment decision, since benign conditions raise CEA, CA 19-9, and CA-125.

Most solid tumor recurrences occur within the first 2 to 3 years, which is why surveillance is front-loaded, but late recurrence in hormone-receptor-positive breast cancer requires surveillance well beyond 5 years.

Last updated: August 2026

4.6 Post-Treatment Surveillance for Cancer Recurrence

Blueprint focus: ONCC Domain I.C.4 — Surveillance for primary cancer recurrence. Distinguish this from Domain I.A.3 (screening survivors for new primaries) and from survivorship care planning. Surveillance asks one question: has the original cancer come back?

The Governing Principle

Surveillance testing is worthwhile only when detecting recurrence earlier than symptoms would produce a better outcome . That test fails more often than clinicians expect.

After curative-intent colorectal resection, it succeeds: isolated liver or lung metastases found early can be resected with curative intent, so intensive imaging and CEA surveillance are standard.

After curative-intent breast surgery, it fails for distant disease: finding asymptomatic metastases earlier has repeatedly failed to improve survival in randomized trials, while generating false positives, radiation exposure, cost, and anxiety. Locoregional recurrence is potentially curable, however, which is why annual mammography and clinical examination remain standard.

This asymmetry explains nearly every disease-specific surveillance recommendation and is the most commonly tested concept in this blueprint item.

Timing: Front-Load the Schedule

Most solid tumor recurrences appear within the first 2 to 3 years , so visits and imaging are concentrated early and then spaced out. The important exception is hormone-receptor-positive breast cancer , where the risk of distant recurrence continues at a low steady rate for 20 years or more — which is why extended endocrine therapy and long-term follow-up are considered.

Disease-Specific Surveillance

Cancer Standard surveillance Explicitly not recommended

Breast (post-curative treatment) History and physical every 3 to 6 months for years 1 to 3, then every 6 to 12 months for years 4 to 5, then annually; annual mammography of remaining breast tissue; annual gynecologic assessment if on tamoxifen; bone density on aromatase inhibitors Routine CT, PET, bone scan, or tumor markers (CA 15-3, CA 27.29, CEA) in asymptomatic patients

Colorectal (stage II to III after resection) History and physical plus CEA every 3 to 6 months for 2 years then every 6 months to 5 years ; CT chest/abdomen/pelvis annually (or more often in high-risk disease) for up to 5 years ; colonoscopy at 1 year, then at 3 years, then every 5 years PET as a routine surveillance modality

Non-small cell lung (after curative therapy) CT chest every 6 months for 2 to 3 years, then annually; annual low-dose CT thereafter for new primaries Routine brain MRI or PET in asymptomatic patients

Prostate (after prostatectomy or radiation) PSA every 6 to 12 months for 5 years then annually ; digital rectal examination annually Routine imaging in the absence of PSA rise or symptoms

Melanoma History and skin/nodal examination at intervals set by stage; imaging for stage IIB and above; lifelong full skin examination Routine imaging for stage IA disease

Lymphoma History, physical, and laboratory studies every 3 to 6 months for 2 years then less often; imaging as clinically indicated Routine surveillance CT or PET in asymptomatic patients in remission, which produces frequent false positives

Head and neck Examination every 1 to 3 months in year 1, tapering thereafter; baseline post-treatment imaging at about 3 months; TSH every 6 to 12 months after neck radiation Indefinite frequent PET

  • Testicular germ cell Stage- and histology-specific schedules of markers (AFP, beta-hCG, LDH) plus imaging —
  • Tumor Markers: Which Ones Actually Work

Marker Validated surveillance use Caution

CEA Colorectal cancer after curative resection Elevated in smoking, hepatic disease, inflammatory bowel disease; not a screening test

PSA Prostate cancer after definitive therapy 5-alpha-reductase inhibitors roughly halve values; benign hyperplasia and prostatitis raise them

AFP, beta-hCG, LDH Germ cell tumors AFP rises in hepatic disease; beta-hCG rises in pregnancy and with marijuana use in some assays

CA-125 Ovarian cancer follow-up (with the caveat that acting on marker rise alone before symptoms has not improved survival) Rises with endometriosis, fibroids, pregnancy, peritoneal irritation

CA 19-9 Pancreatic and biliary cancer trend Not produced in Lewis-antigen-negative individuals (roughly 5% to 10% of people), and rises with biliary obstruction

Thyroglobulin Differentiated thyroid cancer after total thyroidectomy Requires simultaneous anti-thyroglobulin antibody measurement

CA 15-3 / CA 27.29 Not recommended for routine breast cancer surveillance Insufficient specificity to guide asymptomatic management

Interpretation rule: a single elevated value is not a recurrence. Confirm on a repeat specimen from the same laboratory, look at the trend , and correlate with imaging and symptoms before changing treatment.

What Patients Should Be Taught to Report

Symptom-triggered evaluation detects more recurrences than any imaging schedule. Teach patients the specific red flags for their disease and tell them not to wait for the next scheduled visit:

  • New or progressive pain, especially bone pain that is worse at night or at rest
  • Unintentional weight loss, drenching night sweats, persistent fever
  • A new lump, nodule, or change in a surgical scar or nodal basin
  • Persistent cough, hemoptysis, or new dyspnea
  • Change in bowel or bladder habit, rectal bleeding, hematuria

New neurologic symptoms — headache, seizure, focal weakness, or back pain with weakness or bladder change , which is a spinal cord compression emergency

Working Up a Suspected Recurrence

Take a focused history and examination targeted at the symptom.

Obtain disease-appropriate imaging rather than reflexively ordering PET.

Confirm histologically when the result would change management. Biology can change: a hormone-receptor-positive breast cancer can recur as receptor-negative disease, and a new lesion may be a second primary or a benign process.

Re-biopsy for biomarkers at recurrence when resistance mechanisms are actionable — for example EGFR T790M or ESR1 mutations.

Restage completely before treatment; a solitary resectable metastasis is a completely different clinical problem from widespread disease.

Re-establish intent and goals explicitly, since recurrence usually shifts intent from curative to disease control and warrants palliative care integration.

The APRN's Role in Making Surveillance Actually Happen

Surveillance fails through attrition, not through ignorance. Document the schedule in the survivorship care plan, name which clinician orders each test, use recall systems rather than relying on patient memory, address transportation and cost barriers before they cause a missed scan, and manage the fear of recurrence that makes some survivors avoid appointments entirely and others seek unnecessary tests. Explaining why a test is not recommended is as much a part of surveillance as ordering the tests that are.

Loading diagram... Surveillance Logic and Suspected-Recurrence Workup